Molecular structure of BMS-536924, CAS Number: 468740-43-4
BMS-536924 (CAS 468740-43-4)
Alternate Names:
BMS536924 BMS 536924 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone
CAS Number:
468740-43-4
Molecular Weight:
480.00
Molecular Formula:
C25H26ClN5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
BMS-536924 is an ATP-competitive IGF-IR and IR inhibitor.
BMS-536924 (CAS 468740-43-4) References
- 2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924. | Saulnier, MG., et al. 2008. Bioorg Med Chem Lett. 18: 1702-7. PMID: 18258427
- HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. | Haluska, P., et al. 2008. Mol Cancer Ther. 7: 2589-98. PMID: 18765823
- The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. | Huang, F., et al. 2009. Cancer Res. 69: 161-70. PMID: 19117999
- BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. | Litzenburger, BC., et al. 2009. Clin Cancer Res. 15: 226-37. PMID: 19118050
- BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. | Beauchamp, MC., et al. 2009. Gynecol Oncol. 115: 193-8. PMID: 19699512
- Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. | Wahner Hendrickson, AE., et al. 2009. Cancer Res. 69: 7635-43. PMID: 19789352
- Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. | Hou, X., et al. 2011. Mol Cancer Ther. 10: 117-25. PMID: 21220496
- IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. | Dool, CJ., et al. 2011. Endocr Relat Cancer. 18: 699-709. PMID: 21946410
- BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo. | Zhou, Q. 2015. Onco Targets Ther. 8: 689-97. PMID: 25897243
- CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis. | Hua, J., et al. 2022. Mol Cancer. 21: 123. PMID: 35668527
Inhibitor of:
ACAT-1, BZW1, IGF-I, IGF-IA, IGF-IB, IGF-IIR, IGF-IRα, IGFBP3, IGFBP6, IGRP, insulin R, IRS-1, R-Ras, T-cadherin, and VE-cadherin.Activator of:
IGF-II, IRS-2, and IRS-4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BMS-536924, 5 mg | sc-507397 | 5 mg | $285.00 |